CDKN2A and melanoma: Although p16INK4a loss-of-function is an early event observed in >60% of human melanomas, germline mutations affecting p16INK4a are insufficient to drive the disease in mice or humans (Bishop et al, 2000; Shain et al, 2015b; Hennessey et al, 2017).